425: Globalink Amends Merger Terms with Alps Life Sciences

Globalink Investment Inc. and Alps Life Sciences Inc. amended their merger agreement, adjusting escrow share contributions and extending the shareholder consent deadline.

Summary

• Globalink Investment Inc. and Alps Life Sciences Inc. (Alps Holdco) entered into a Third Amendment to their Amended and Restated Merger Agreement on September 27, 2025.
• The amendment allows Dr. Tham Seng Kong, in his personal capacity, to contribute all Escrow Shares from his personal entitlement of Merger Consideration Shares.
• The Alps Holdco Shareholder Written Consent Deadline has been extended to be as promptly as reasonably practicable after the F-4 Effective Date and in any event prior to the Effective Time.
• The Escrow Amount, equal to 5% of the Merger Consideration (valued at $10.00 per share), will be held in a segregated escrow account.
• Dr. Tham Seng Kong is designated as the sole contributing Alps Holdco Shareholder for the Escrow Property, which will be released and transferred to him upon disbursement.
• The Escrow Property serves as the sole source of payment for Alps Holdco Shareholders' obligations pursuant to Article XII of the agreement.
• Indemnification claims against the Escrow Property are generally limited to six months after the Closing Date, with provisions for pending claims.

Sentiment

Score: 6

Explanation: The amendment addresses procedural aspects of an ongoing merger, clarifying escrow arrangements and extending a deadline. While the extension could imply minor delays, the overall intent is to facilitate the transaction, which is a neutral to slightly positive development for deal completion. The concentration of escrow responsibility to one individual is a notable structural change.

Positives

• Clarification of escrow arrangements, potentially streamlining the merger process.
• Extension of the Alps Holdco Shareholder Written Consent Deadline provides more time for necessary approvals.

Negatives

• Concentration of escrow share contribution and subsequent release to a single individual (Dr. Tham Seng Kong) could introduce specific dependencies.
• The need for an amendment suggests potential complexities or adjustments in the original merger timeline or terms.

Risks

• Risks related to the consummation of the proposed Transactions, including potential delays or failure to consummate, failure to obtain stockholder approval, failure to secure regulatory approvals, and other unmet conditions.
• Effects of any termination of the Merger Agreement on Globalink or Alps Holdco, including a significant decline in Globalink's stock price if the transactions are not completed.
• Disruption to PubCo's, Globalink's, or Alps Holdco's current plans and operations due to the announcement or pendency of the proposed Transactions.
• Inability to recognize the anticipated benefits of the proposed Transactions.
• Unexpected costs resulting from the proposed Transactions.
• Changes in general economic conditions, regulatory conditions and developments, or applicable laws or regulations.
• Nature, cost, and outcome of pending and future litigation and other legal proceedings, including those related to the proposed Transactions.

Future Outlook

The filing contains forward-looking statements regarding the consummation of the proposed transactions, anticipated benefits, and potential risks, but no specific financial guidance or projections. It emphasizes that actual results may differ materially from expectations due to various factors, including risks related to transaction completion, regulatory approvals, and general economic conditions.

Management Comments

• Management of Globalink, Alps Holdco, and PubCo consider the estimates and assumptions underlying forward-looking statements to be reasonable, though inherently uncertain.
• The parties involved (Globalink, Alps Holdco, Parent Representative, Seller Representative) have agreed to the terms of the Third Amendment to the Merger Agreement to facilitate the ongoing business combination.

Industry Context

This amendment is a procedural step in the ongoing SPAC business combination between Globalink and Alps Life Sciences. Such amendments are common in complex merger processes to clarify terms, address unforeseen issues, or adjust timelines, reflecting the dynamic nature of deal execution in the financial industry.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The filing mentions the risk of "pending and future litigation and other legal proceedings, including any such proceedings related to the proposed Transactions and instituted against PubCo, Globalink, Alps Holdco and others." No specific new proceedings are detailed.

Related Party Transactions

• Dr. Tham Seng Kong, in his personal capacity and as the Seller Representative, is designated as the sole contributing Alps Holdco Shareholder for the Escrow Shares, which will be released and transferred to him upon disbursement. This is a specific arrangement involving a key individual in the transaction.

Stakeholder Impact

• Shareholders (Globalink): Will need to vote on the proposed business combination. The amendment aims to facilitate the merger, potentially leading to the anticipated benefits of the combined entity.
• Shareholders (Alps Holdco): Required to provide written consent. Dr. Tham Seng Kong's personal involvement in the escrow mechanism directly impacts his share entitlement.
• Management: Involved in negotiating and executing the amendment to ensure the merger proceeds.
• Regulatory Authorities (SEC): Will review the Form F-4 registration statement and proxy statement/prospectus.

Next Steps

• PubCo to file a registration statement on Form F-4 (Registration No. 333-284035) including a proxy statement/prospectus with the SEC.
• Globalink's stockholders to vote on the proposed business combination.
• Alps Holdco to obtain and deliver the Alps Holdco Shareholder Written Consent prior to the Effective Time.
• Parent Representative, Seller Representative, and Escrow Agent to enter into an Escrow Agreement at or prior to the Closing.
• Consummation of the proposed Transactions.

Key Dates

Recommendation

The filing details a procedural amendment to an existing merger agreement, primarily clarifying escrow arrangements and extending a shareholder consent deadline. These are standard steps in complex business combinations and do not introduce new material financial information or significant strategic shifts that would warrant a change in investment thesis. Investors should hold pending the completion of the merger and the release of more comprehensive financial and operational details of the combined entity. The extension of the consent deadline suggests minor procedural adjustments rather than fundamental issues, maintaining a neutral outlook on the deal's prospects.

Keywords

SPAC, Merger Agreement, Amendment, Escrow Shares, Shareholder Consent, Business Combination, Globalink, Alps Life Sciences, SEC Filing, Form 8-K